Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age

Completed · Phase 2 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

The study determined the safety of CNP520 in healthy elderly over 3 months. Data relevant for Pharmacokinetic/Pharmacodynamic modeling were obtained in order to define the target dose in subsequent efficacy studies.

Key facts

Study ID

NCT02576639

Run by

Novartis Pharmaceuticals

People needed

124

Starts

2015-08-10

Expected to finish

2016-03-11

Last updated by the study team

2017-08-11

Who can join

Age: 60 and older, up to 80. Sex: any. Healthy volunteers: accepted.

Where it is running

• Novartis Investigative Site — Glendale, California, United States
• Novartis Investigative Site — Long Beach, California, United States
• Novartis Investigative Site — Miami, Florida, United States
• Novartis Investigative Site — Lincoln, Nebraska, United States
• Novartis Investigative Site — Antwerp, Belgium
• Novartis Investigative Site — Berlin, Germany
• Novartis Investigative Site — Groningen, GZ, Netherlands
• Novartis Investigative Site — Leiden, Netherlands
• Novartis Investigative Site — Belfast, Northern Ireland, United Kingdom
• Novartis Investigative Site — Harrow, United Kingdom
• Novartis Investigative Site — Mid Glamorgan, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.